• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Perinatal MOUD Use and Infant Discharge to Biological Parents
Research Update

Perinatal MOUD Use and Infant Discharge to Biological Parents

October 31, 2023
Destiny Pegram, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Destiny Pegram, MD. Dr. Pegram has no financial relationships with companies related to this material.

REVIEW OF: Singleton R et al, J Addict Med 2022;16(6):e366–e373

STUDY TYPE: Retrospective chart review

As the prevalence of opioid use disorder (OUD) continues to rise, so too does the rate of opioid use during pregnancy. Once born, many of these infants never get the chance to go home with a biological parent and are instead referred to the child welfare system, leaving many pregnant patients reluctant to seek OUD treatment. This trend is especially pronounced in minority populations, with minority children disproportionately represented in the child welfare system due to parental substance use. We know that the use of medications for opioid use disorder (MOUD) is associated with a host of positive health outcomes, but does avoiding this treatment paradoxically increase the likelihood that a baby will get to go home with their biological parent?

The authors of this recent study were interested in the impact of MOUD among pregnant Native American and Alaska Native patients. They conducted a retrospective chart review at three Alaskan hospitals and identified 193 patients with OUD who had recently given birth to a full-term infant. About half of the patients (47%) were receiving an MOUD at the time of delivery (buprenorphine or methadone), while the other half were using non-prescribed opioids such as heroin. 

Overall, 70% of the infants were discharged home with their biological parent(s), 13% were discharged to a relative, 13% went directly into foster care, and a few were transferred to another hospital or addiction treatment unit. Crucially, patients taking an MOUD were more likely to leave the hospital with their baby (OR=3.9; 95% confidence interval [CI]=1.5–9.2; p=0.005). On the flip side, prenatal heroin use was associated with a lower likelihood of the baby going home with a biological parent (OR=0.11; 95% CI=0.04–0.28; p=0.0001). Proper prenatal care was associated with a greater likelihood that the baby would be discharged with a biological parent (OR=3.7; 95% CI=1.5–9.2; p=0.005) and also increased the likelihood that the patient would receive an MOUD while pregnant (p<0.001). 

CARLAT TAKE

Some have feared that MOUD treatment during pregnancy could lead to infants being placed in foster care, especially among minority populations. On the contrary, at least in this study, MOUD was associated with an increased likelihood that newborns would go home with a biological parent. This study underscores the importance of good prenatal care and MOUD treatment for our pregnant patients.

Addiction Treatment Research Update
KEYWORDS addiction medication for opioid use disorder opioid use disorder pregnancy
    Destiny Pegram, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: November 3, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Benzodiazepines, CATR, October/November/December 2023
    Benzodiazepines: The Basics and Beyond
    Deprescribing Benzos: A How-To Guide
    When and How Should We Prescribe Benzos?
    Xylazine: An Emerging Threat in the Opioid Overdose Epidemic
    Can Psilocybin Treat Alcohol Use Disorder?
    Perinatal MOUD Use and Infant Discharge to Biological Parents
    CME Post-Test, Benzodiazepines, CATR, October/November/December 2023
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.